Advances in ISSN: 2378-3168 AOWMC

Obesity, Weight Management & Control
Opinion
Volume 8 Issue 6

Role of central and peripheral serotonin in obesity: what to expect in the near pharmacotherapy future?

Mina T Kelleni1,2
1Department of Pharmacology, Jouf University, Kingdom of Saudi Arabia
2Department of Pharmacology, Minia University, Egypt
Received: July 29, 2018 | Published: November 09, 2018

Correspondence: Mina T Kelleni MD, PhD, Department of Pharmacology, College of Medicine, Jouf University, Sakaka, Kingdom of Saudi Arabia, Tel +966560407874 Email

Citation: Kelleni MT. Role of central and peripheral serotonin in obesity: what to expect in the near pharmacotherapy future? Adv Obes Weight Manag Control. 2018;8(6):291. DOI: 10.15406/aowmc.2018.08.00261

Opinion

Obesity currently represents a global epidemic disease, amounting for an estimated $147 billion in health care spending annually in USA only, and associated with cardiovascular and cerebrovascular diseases.1 Regarding the pathogenesis, it's well known that obesity results from an imbalance between energy intake and expenditure, and a hypothesis that is widely accepted states that increased food intake is partially driven by decreased dopamine-mediated reward and decreased serotonin, (5-hydroxytryptamine [5-HT]), mediated homeostatic feedback in response to food intake.2 Central serotonergic system is known to elicit satiety signal as well as to elevate the mood and evidence suggested a positive and bidirectional association between obesity and depression.3 Interestingly, not only central serotonin plays a role in obesity pathogenesis, but also peripheral serotonin was suggested to play an important role in obesity, and evidence from animal studies has demonstrated 5-HT ability to regulate glucose and lipid metabolism by accelerating energy consumption in skeletal muscle. Further, gut-derived 5-HT was likely suggested to be an important driver of pathogenesis in human obesity as well as in dysglycemia4,5 and several genetic polymorphisms in tryptophan hydroxylase and 5-HT receptors were shown to have strong associations with obesity. Moreover, peripheral 5-HT was shown to suppress the adaptive thermo genesis in brown adipose tissue and the peripheral serotonergic system was marked as a therapeutic target for both obesity and diabetes.6 Lorcaserin, 5-HT2 receptor agonist, and its potential under development more specific congeners with lower adverse effects, suppress the appetite and reduce body weight gain and are considered as promising therapeutic tools for obesity7 while antagonism of 5-HT2c receptor has been identified as a main cause of second generation antipsychotics induced weight gain and obesity.8 On the other hand, obesity increases peripheral serotonin and inhibiting serotonin signaling or its synthesis in adipose tissue may be an effective treatment for obesity and its comorbidities.9

Acknowledgements

None.

Conflict of interest

Author declares that there is no conflict of interest.

References

©2018 Kelleni. This is an open access article distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and build upon your work non-commercially.
© 2014-2019 MedCrave Group, All rights reserved. No part of this content may be reproduced or transmitted in any form or by any means as per the standard guidelines of fair use.
Creative Commons License Open Access by MedCrave Group is licensed under a Creative Commons Attribution 4.0 International License.
Based on a work at https://medcraveonline.com
Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version | Opera |Privacy Policy